◆ TICKERBASE交互式视图 →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

首页全部股票 › ZTS · English version

Zoetis Inc (ZTS)

来自官方财务报表的收入、利润与现金流历史。

Health Care · 华尔街(美国) · 最近更新: 2026-09-17

Zoetis Inc. 致力于美国和国际动物保健行业的药品、疫苗、诊断产品和服务、生物设备、基因测试和精准动物保健解决方案的发现、开发、制造和商业化。该公司主要将产品商业化于伴侣动物,包括狗、猫和马;和物种,包括牲畜,如牛、猪、家禽、鱼和羊。它还提供杀虫剂、疫苗、皮肤科、抗感染药、止痛药和镇静药、其他药物和动物健康诊断。此外,该公司还提供动物健康诊断,包括即时诊断产品、仪器和试剂、快速免疫分析测试、参考实验室套件和服务以及血糖监测仪;和其他非药品产品,包括营养品以及生物设备、基因测试和精准动物健康领域的产品和服务。该公司向兽医、牲畜生产者和宠物主人销售其产品。该公司与 Blacksmith Medicines, Inc. 合作,发现和开发用于动物健康的新型抗生素。 Zoetis Inc.成立于2012年,总部位于新泽西州帕西帕尼。

机器翻译

关键数据

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
总收入$9.5B$9.5B$9.3B$8.5B$8.1B$7.8B$6.7B$6.3B$5.8B$5.3B$4.9B$4.8B$4.8B$4.6B$4.3B$4.2B$3.6B$2.8B
毛利$6.7B$6.7B$6.4B$5.8B$5.5B$5.3B$4.5B$4.1B$3.8B$3.4B$3.1B$3.0B$3.0B$2.8B$2.7B$2.5B$2.1B$1.7B
毛利率%70.9%70.5%69.1%68.3%67.8%68.3%66.8%65.7%65.2%64.9%64.3%62.3%62.9%62.1%62.7%60.0%58.2%61.7%
营业利润(EBIT)$3.5B$3.6B$3.4B$3.1B$2.9B$2.8B$2.3B$2.0B$1.9B$1.7B$1.4B$1.1B$970M$821M$854M$684M$309M$281M
营业利润率%37.0%38.0%36.6%35.9%36.2%36.0%34.0%32.2%32.3%32.5%28.7%22.7%20.3%18.0%19.7%16.2%8.6%10.2%
净利$2.6B$2.7B$2.5B$2.3B$2.1B$2.0B$1.6B$1.5B$1.4B$864M$821M$339M$583M$504M$436M$245M$110M($100M)
净利润率 %27.5%28.2%26.9%27.4%26.2%26.2%24.5%24.0%24.5%16.3%16.8%7.1%12.2%11.1%10.1%5.8%3.1%-3.6%
EBITDA$3.9B$4.1B$3.9B$3.7B$3.4B$3.2B$2.7B$2.5B$2.2B$1.9B$1.6B$868M$1.1B$1.0B$941M$635M$400M$2M
每股收益(EPS)$6.08$6.02$5.47$5.07$4.49$4.27$3.42$3.11$2.93$1.75$1.65$0.68$1.16$1.01$0.87$0.51$0.23$-0.21
已发行股数 (M)418M444M455M462M470M477M479M482M487M493M498M502M502M500M500M482M482M482M

来源:公司公开报告(SEC)。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 ZTS 交互式查看器。 /companies/us/ZTS

类似公司

本网站信息仅用于教育与参考,不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.